| By Ellen Johnson | | Macroaxis Story | |
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using
Portfolio Positions Ratings and
Equity Ratings tools to further calibrate your research.
Story appears to be empty
IRIDEX (IRIX)
The company has return on total asset
(ROA) of
(0.163) % which means that it has lost $0.163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.7154) %, meaning that it created substantial loss on money invested by shareholders. IRIDEX's management efficiency ratios could be used to measure how well IRIDEX manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to rise to -0.21 in 2024.
Return On Capital Employed is likely to rise to -0.28 in 2024. At this time, IRIDEX's
Total Assets are fairly stable compared to the past year.
Non Currrent Assets Other is likely to rise to about 1.5
M in 2024, whereas
Non Current Assets Total are likely to drop slightly above 4.4
M in 2024. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 49.08
M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate IRIDEX's market, we take the total number of its shares issued and multiply it by IRIDEX's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be
undervalued.
IRIDEX retains a regular
Real Value of $3.19 per share. The prevalent price of the firm is $3.02. Our model calculates the value of
IRIDEX from analyzing the firm
fundamentals such as Return On Equity of -0.72,
return on asset of -0.16, and Operating Margin of
(0.25) % as well as examining its
technical indicators and
probability of bankruptcy. In general, most investors encourage acquiring undervalued assets and dropping overvalued assets since, at some point future time, asset prices and their ongoing
real values will come together.
GenMark Diagnostics (GNMK)
The company has return on total asset (ROA) of (2.63) % which means that it has lost $2.63 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.06) %, meaning that it created substantial loss on money invested by shareholders. GenMark Diagnostics' management efficiency ratios could be used to measure how well GenMark Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.77 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GenMark Diagnostics's market, we take the total number of its shares issued and multiply it by GenMark Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Globus Medical (GMED)
The company has return on total asset
(ROA) of
0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024,
Return On Tangible Assets is expected to decline to 0.04. In addition to that,
Return On Capital Employed is expected to decline to 0.03. At present, Globus Medical's
Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's
Non Currrent Assets Other is expected to grow to about 82.5
M, whereas
Return On Tangible Assets are forecasted to decline to 0.04. The entity currently falls under 'Mid-Cap' category with a current market capitalization of 6.87
B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Globus Medical's market, we take the total number of its shares issued and multiply it by Globus Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be
fairly valued.
Globus Medical retains a regular
Real Value of $52.17 per share. The prevalent price of the firm is $50.75. Our model calculates the value of
Globus Medical from evaluating the firm
fundamentals such as Return On Asset of 0.0477,
return on equity of 0.0421, and Current Valuation of 6.87
B as well as inspecting its
technical indicators and
probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing
real values will come together.
IsoRay Inc (ISR)
The company has Return on Asset of (0.1085) % which means that on every $100 spent on assets, it lost $0.1085. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1741) %, meaning that it generated no profit with money invested by stockholders. IsoRay's management efficiency ratios could be used to measure how well IsoRay manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Small-Cap' category with a total capitalization of 107 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate IsoRay's market, we take the total number of its shares issued and multiply it by IsoRay's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Current Medical Equipment Recommendations
Watch out for price decline
Please consider monitoring Macroaxis on a daily basis if you are holding a position in it. Macroaxis is trading at a penny-stock level, and the possibility of delisting is much higher compared to other privates. However, just because the private is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Macroaxis stock to be traded above the $1 level to remain listed. If Macroaxis private price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Macroaxis's Liquidity
Macroaxis
financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Macroaxis's total debt and its cash.
Story appears to be empty
IRIDEX (IRIX)
The company has return on total asset
(ROA) of
(0.163) % which means that it has lost $0.163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.7154) %, meaning that it created substantial loss on money invested by shareholders. IRIDEX's management efficiency ratios could be used to measure how well IRIDEX manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to rise to -0.21 in 2024.
Return On Capital Employed is likely to rise to -0.28 in 2024. At this time, IRIDEX's
Total Assets are fairly stable compared to the past year.
Non Currrent Assets Other is likely to rise to about 1.5
M in 2024, whereas
Non Current Assets Total are likely to drop slightly above 4.4
M in 2024. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 49.08
M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate IRIDEX's market, we take the total number of its shares issued and multiply it by IRIDEX's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be
undervalued.
IRIDEX retains a regular
Real Value of $3.19 per share. The prevalent price of the firm is $3.02. Our model calculates the value of
IRIDEX from analyzing the firm
fundamentals such as Return On Equity of -0.72,
return on asset of -0.16, and Operating Margin of
(0.25) % as well as examining its
technical indicators and
probability of bankruptcy. In general, most investors encourage acquiring undervalued assets and dropping overvalued assets since, at some point future time, asset prices and their ongoing
real values will come together.
GenMark Diagnostics (GNMK)
The company has return on total asset (ROA) of (2.63) % which means that it has lost $2.63 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.06) %, meaning that it created substantial loss on money invested by shareholders. GenMark Diagnostics' management efficiency ratios could be used to measure how well GenMark Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.77 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GenMark Diagnostics's market, we take the total number of its shares issued and multiply it by GenMark Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Globus Medical (GMED)
The company has return on total asset
(ROA) of
0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024,
Return On Tangible Assets is expected to decline to 0.04. In addition to that,
Return On Capital Employed is expected to decline to 0.03. At present, Globus Medical's
Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's
Non Currrent Assets Other is expected to grow to about 82.5
M, whereas
Return On Tangible Assets are forecasted to decline to 0.04. The entity currently falls under 'Mid-Cap' category with a current market capitalization of 6.87
B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Globus Medical's market, we take the total number of its shares issued and multiply it by Globus Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be
fairly valued.
Globus Medical retains a regular
Real Value of $52.17 per share. The prevalent price of the firm is $50.75. Our model calculates the value of
Globus Medical from evaluating the firm
fundamentals such as Return On Asset of 0.0477,
return on equity of 0.0421, and Current Valuation of 6.87
B as well as inspecting its
technical indicators and
probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing
real values will come together.
IsoRay Inc (ISR)
The company has Return on Asset of (0.1085) % which means that on every $100 spent on assets, it lost $0.1085. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1741) %, meaning that it generated no profit with money invested by stockholders. IsoRay's management efficiency ratios could be used to measure how well IsoRay manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Small-Cap' category with a total capitalization of 107 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate IsoRay's market, we take the total number of its shares issued and multiply it by IsoRay's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Current Medical Equipment Recommendations
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
